Pfizer will halt its development of a weight-loss drug that was being closely watched by investors, in a significant blow to the US pharmaceutical group.
辉瑞(Pfizer)将停止开发其备受投资者关注的减肥药，这对这家美国制药集团来说是一个重大打击。
您已阅读5%（201字），剩余95%（3873字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。